πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Immunovant, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

INmune Bio, Inc.

INmune Bio, Inc. logo
Market Cap: Low
Employees: Lowest

INKmune

INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.

Tags: Alzheimer's disease, chronic inflammation, hematologic malignancies, immunotherapy, solid tumors

Symbol: INMB

Recent Price: $4.65

Industry: Biotechnology

CEO: Dr. Raymond Joseph Tesi M.D.

Sector: Healthcare

Employees: 11

Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432

Phone: 858 964 3720

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

BDC-1001

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology agents that target tumor cells for immune system elimination.

Tags: HER2, biotechnology, cancer treatment, clinical-stage, immuno-oncology

Symbol: BOLT

Recent Price: $0.57

Industry: Biotechnology

CEO: Mr. William P. Quinn

Sector: Healthcare

Employees: 100

Address: 900 Chesapeake Drive, Redwood City, CA 94063

Phone: 650 665 9295

Last updated: 2024-12-31

Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Cosibelimab

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on acquiring, developing, and commercializing novel treatments for solid tumor cancers. Their lead product candidates include Cosibelimab, a fully-human monoclonal antibody, and other treatments for various cancer targets.

Tags: Antibody, Cancer Treatment, Cosibelimab, EGFR Inhibitor, Immunotherapy, Oncology

Symbol: CKPT

Recent Price: $3.35

Industry: Biotechnology

CEO: Mr. James F. Oliviero III, C.F.A.

Sector: Healthcare

Employees: 23

Address: 95 Sawyer Road, Waltham, MA 02453

Phone: 781 652 4500

Last updated: 2024-12-31

Immunome, Inc.

Immunome, Inc. logo
Market Cap: Medium
Employees: Low

IMM-ONC-01, IMM-BCP-01

Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.

Tags: antibody therapeutics, biopharmaceutical, infectious disease, oncology

Symbol: IMNM

Recent Price: $10.28

Industry: Biotechnology

CEO: Dr. Clay B. Siegall Ph.D.

Sector: Healthcare

Employees: 78

Address: 665 Stockton Drive, Exton, PA 19341

Phone: 610 321 3700

Last updated: 2024-12-31

Immunic, Inc.

Immunic, Inc. logo
Market Cap: Low
Employees: Low

IMU-838

Immunic, Inc. develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, in Phase 2 clinical trials for multiple conditions, including relapsing-remitting multiple sclerosis.

Tags: autoimmune diseases, biopharmaceutical, chronic inflammatory diseases, clinical trials, immunology, therapies

Symbol: IMUX

Recent Price: $1.03

Industry: Biotechnology

CEO: Dr. Daniel Vitt Ph.D.

Sector: Healthcare

Employees: 85

Address: 1200 Avenue of the Americas, New York, NY 10036

Phone: 332 255 9818

Last updated: 2024-12-31

Immunovant, Inc.

Immunovant, Inc. logo
Market Cap: High
Employees: Low

batoclimab

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases, including batoclimab for myasthenia gravis and thyroid eye disease.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, monoclonal antibodies

Symbol: IMVT

Recent Price: $23.88

Industry: Biotechnology

CEO: Dr. Peter Salzmann M.B.A., M.D.

Sector: Healthcare

Employees: 207

Address: 320 West 37th Street, New York, NY 10018

Phone: 917 580 3099

Leadership

  • Pete Salzmann, M.D., MBA, Chief Executive Officer
  • Renee Barnett, MBA, Chief Financial Officer
  • Christine Blodgett, Senior Vice President of Human Resources
  • Andy Deig, Senior Vice President Strategic Finance
  • Michael Geffner M.D., MBA, Chief Medical Officer
  • Julie Kirschling, Senior Vice President, Program and Alliance Management
  • Mark Levine, Chief Legal Officer and Corporate Secretary
  • Bill Macias, M.D., Ph.D., Chief Medical Officer
  • Becky Merlina, Senior Vice President, Global Head of Quality
  • Jody Roth, MS, RAC, PMP, Senior Vice President, Regulatory Affairs
  • Jay S. Stout, PhD, Chief Technology Officer
  • Yan Zheng, Ph.D., Senior Vice President Biostatistics, Programming & Data Management
  • Chandra Adams, Vice President, Associate General Counsel
  • Maria Alba, M.D., Vice President of Clinical Development
  • Farah Ali, Vice President, Clinical Development
  • Jennifer Ashley, Vice President, Associate General Counsel
  • Annetta Beauregard, Vice President, Regulatory Affairs Strategy
  • Harry Berlanga, MSc., VP, CMC & Distribution Quality
  • Ranjit Deshmukh, Ph.D., Vice President of CMC and Technical Operations
  • Scott Forman, MBA, Vice President, Program Management
  • Tom Forman, MBA, Vice President, CMC Project Management
  • Ian Gourley, M.D., Vice President of Clinical Development
  • Thomas Hardy, M.D., Ph.D., Vice President of Drug Safety and Pharmacovigilance
  • Laci Hasenour, Vice President Marketing, Neurology
  • Aileen Ilaria, MBA, Vice President, Clinical Operations – Global Site Management
  • Claudia Jacobs, Ph.D., Vice President of CMC Project Management Operations and Clinical Supply
  • Jonathan Janes, MB, Vice President Clinical Development
  • Ant Kidwell, Vice President of IT and Facilities
  • Chedvi Levin-Sister, Vice President of Finance
  • Launi Masterson, Vice President of Clinical Operations
  • Andy Minke, Vice President Program Management
  • Linda McKerral, Vice President, CMC Analytical Sciences
  • Pooja Mehta, Vice President Drug Substance Tech Transfer
  • Regina Mirra, VP, Regulatory Operational Excellence
  • Jennifer Moseley, Vice President of Clinical Operations
  • Sheetal Patel M.D., MS MBA, Vice President of Clinical Development
  • Cassandra Pauyo, Vice President, Data Management
  • Rod Saponjic Ph.D., MBA, Vice President of Clinical Operations
  • Lauren Schrier, MBA, Vice President of Marketing
  • Frank Torti, M.D., Chairperson of Board of Directors
  • Andrew Fromkin, Member of Board of Directors
  • Douglas Hughes, Member of Board of Directors
  • George Migausky, Member of Board of Directors
  • Atul Pande, M.D., Member of Board of Directors
  • Eric Venker, M.D., Pharm.D., Member of Board of Directors

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Moleculin Biotech, Inc.

Moleculin Biotech, Inc. logo
Market Cap: Lowest
Employees: Lowest

Annamycin

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing drug candidates for highly resistant tumors and viruses. Its lead product, Annamycin, is in Phase 1/2 studies, and it also works on other candidates targeting brain tumors, pancreatic cancer, and COVID-19.

Tags: Biotech, Cancer treatment, Clinical-stage, Drug development, Pharmaceutical, Phase 1/2 studies

Symbol: MBRX

Recent Price: $1.79

Industry: Biotechnology

CEO: Mr. Walter V. Klemp

Sector: Healthcare

Employees: 18

Address: 5300 Memorial Drive, Houston, TX 77007

Phone: 713 300 5160

Last updated: 2024-12-31

NexImmune, Inc.

NexImmune, Inc. logo
Market Cap: Lowest
Employees: Lowest

Artificial Immune Modulation

Nex Immune, Inc., a clinical-stage biotechnology company, develops therapies for cancer and immune-mediated diseases using its Artificial Immune Modulation platform. The company is advancing cell therapy candidates including NEXI-001, NEXI-002, and NEXI-003.

Tags: T cell immunotherapies, biotechnology, cancer, cell therapy, immune-mediated diseases, nanoparticle technology

Symbol: NEXI

Recent Price: $0.15

Industry: Biotechnology

CEO: Mr. John Trainer M.B.A.

Sector: Healthcare

Employees: 6

Address: 9119 Gaither Road, Gaithersburg, MD 20877

Phone: 301 825 9810

Leadership

  • Kristi Jones, Chief Executive Officer
  • Mathias Oelke, Ph.D., Chief Scientific Officer
  • Daniel Bednarik Ph.D., Senior Vice President, Molecular Engineering & Protein Design
  • Jack Ragheb, Senior Vice President, Translational Science
  • Tonya Catterton, Vice President, Quality & Compliance
  • Tim Stover, Vice President, Corporate Controller
  • Karen Haslbeck, Head, Human Resources
  • Matt Schiller, Head, Business Development

Last updated: 2024-12-31

Ocean Biomedical, Inc.

Ocean Biomedical, Inc. logo
Market Cap: Lowest
Employees: Lowest

Humanized Monoclonal Antibodies, Small Molecule Candidates, Malaria Vaccine

Ocean Biomedical, Inc. is a biopharmaceutical company that develops therapeutic products for oncology, fibrosis, infectious diseases, and inflammation, with a focus on innovative treatments like monoclonal antibodies targeting Chi3l1 and small molecules targeting Chit1.

Tags: biopharmaceutical, fibrosis, infectious diseases, inflammation, monoclonal antibodies, oncology, small molecules

Symbol: OCEA

Recent Price: $0.60

Industry: Biotechnology

CEO: Dr. Jack A. Elias M.D.

Sector: Healthcare

Employees: 9

Address: Room 325, 55 Claverick Street, Providence, RI 02903

Phone: 401-444-7375

Last updated: 2024-12-31

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SAB-185, SAB-176

SAB Biotherapeutics is a clinical-stage biopharmaceutical company focusing on developing immunotherapies based on human antibodies, using advanced genetic engineering to produce fully-human polyclonal antibodies targeting diseases such as COVID-19, influenza, autoimmune disorders, and cancer.

Tags: COVID-19, autoimmune disorders, biopharmaceutical, cancer, human antibodies, immunotherapy, influenza

Symbol: SABS

Recent Price: $4.15

Industry: Biotechnology

CEO: Mr. Samuel J. Reich

Sector: Healthcare

Employees: 57

Address: 2100 East 54th Street North, Sioux Falls, SD 57104

Phone: 605 679 6980

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

XBiotech Inc.

XBiotech Inc. logo
Market Cap: Low
Employees: Low

True Human monoclonal antibodies

XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies targeting inflammatory and infectious diseases, with additional development in interleukin-1 alpha therapies for various medical conditions and COVID-19 therapy.

Tags: COVID-19, antibodies, biopharmaceutical, cancer, diseases, inflammation, therapies

Symbol: XBIT

Recent Price: $4.09

Industry: Biotechnology

CEO: Mr. John Simard

Sector: Healthcare

Employees: 94

Address: 5217 Winnebago Lane, Austin, TX 78744

Phone: 512 386 2900

Last updated: 2024-12-31

Xencor, Inc.

Xencor, Inc. logo
Market Cap: High
Employees: Low

Monoclonal Antibody and Cytokine Therapeutics

Xencor, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibody and cytokine therapeutics for treating cancer and autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, cancer treatment, cytokines, monoclonal antibodies

Symbol: XNCR

Recent Price: $23.71

Industry: Biotechnology

CEO: Dr. Bassil I. Dahiyat Ph.D.

Sector: Healthcare

Employees: 280

Address: 111 West Lemon Avenue, Monrovia, CA 91016

Phone: 626 305 5900

Last updated: 2024-12-31

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation logo
Market Cap: Medium
Employees: Medium

immunoSEQ

Adaptive Biotechnologies Corporation is a commercial-stage company that develops an immune medicine platform for diagnosing and treating various diseases, including COVID-19 and lymphoid cancers.

Tags: COVID-19, cancer, diagnostics, immune medicine, immunosequencing, translational research

Symbol: ADPT

Recent Price: $6.11

Industry: Biotechnology

CEO: Mr. Chad M. Robins M.B.A.

Sector: Healthcare

Employees: 709

Address: 1165 Eastlake Avenue East, Seattle, WA 98109

Phone: 206 659 0067

Last updated: 2024-12-31

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. logo
Market Cap: Lowest
Employees: Lowest

APVO436

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapeutic candidates to treat various forms of cancer, with a primary focus on APVO436, a bispecific T-cell engaging antibody for leukemia and myelodysplastic syndrome.

Tags: biotechnology, bispecific antibodies, cancer treatment, clinical-stage, immunotherapy

Symbol: APVO

Recent Price: $4.78

Industry: Biotechnology

CEO: Mr. Marvin L. White

Sector: Healthcare

Employees: 40

Address: 2401 4th Avenue, Seattle, WA 98121

Phone: 206 838 0500

Leadership

  • Marvin L. White, President and Chief Executive Officer
  • Jeff Lamothe, EVP and Chief Operating Officer
  • Daphne Taylor, SVP and Chief Financial Officer
  • Dirk Huebner, M.D., Chief Medical Officer
  • SoYoung Kwon, SVP, General Counsel, Business Development and Corporate Affairs

Last updated: 2024-12-31